Unlocking KRAS: Turning Science into Survival

Aug 17, 2026 - By Erin Post For decades, pancreatic cancer research was defined by what seemed to be impossible. Researchers couldn’t target the mutations in the RAS family of proteins that drive more than 90% of cases. Often described as a “smooth ball,” the RAS protein is frustratingly free of any pockets or divots that would allow a drug to bind to it. Researchers deemed it “undruggable.” Not…